Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors)
against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and …

ABSTRACT Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-
threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes …

Introduction A recombinant porcine factor VIII B‐domain‐deleted product (rp FVIII; OBIZUR,
Baxalta Incorporated, Deerfield, IL 60015, USA) was recently approved for treatment of …

Introduction A recently developed method to assess comprehensive coagulation function,
clot waveform analysis (CWA), accurately detect low levels (< 1 IU/dL) of factor VIII activity …

Background. Acquired hemophilia A (AHA) is a rare condition, due to the spontaneous
formation of neutralizing antibodies against endogenous factor VIII. About half the cases are …

Acquired haemophilia A (AHA) is a rare, serious bleeding disorder most often encountered
in elderly patients. The mainstay of haemostatic management is with bypassing agents …

Introduction Patients with acquired haemophilia A (AHA) have autoantibodies against factor
VIII (FVIII), and may develop spontaneous bleeding that requires treatment with FVIII …

The article focuses on the study related to the treatment of an autoimmune disorder acquired
by haemophilia A (AHA) which is caused by the development of blood coagulation factor VIII …

Rare diseases are defined as life-threatening or chronically debilitating diseases with a
prevalence of less than one per 2000 according to the European Union or one per 1250 …

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies
against clotting factor VIII (FVIII). With an estimated annual incidence of 1.3 to 1.5 per million …